820 results on '"Uy, Geoffrey L."'
Search Results
2. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
3. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
4. Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?
5. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
6. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
7. Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes
8. Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma
9. Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes
10. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis
11. Machine learning–based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors
12. Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
13. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
14. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL
15. Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action
16. Phase I Study of Duvelisib Study for Cytokine Release Syndrome Prophylaxis in Patients Receiving Chimeric Antigen Receptor T Cell Treatment for Non-Hodgkin Lymphoma
17. Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS
18. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
19. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses
20. Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia
21. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
22. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.
23. CD123 bi-specific antibodies in development in AML: What do we know so far?
24. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia
25. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
26. Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.
27. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
28. Clinical and functional significance of circular RNAs in cytogenetically normal AML
29. Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)
30. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
31. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
32. Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
33. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
34. A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
35. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study
36. Choosing induction chemotherapy in therapy-related acute myeloid leukemia
37. Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
38. Association of social deprivation with survival in younger adult patients with AML: an Alliance study
39. Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically
40. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia
41. Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia
42. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma
43. Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials
44. Abstract 4342: Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes
45. Data from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
46. Supplementary Tables from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
47. Supplementary Methods from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
48. Supplementary Figures from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
49. Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation
50. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.